StockTipsArenaBeta

BUY Jubilant Ingrevia Limited — Kotak Securities

BUYJubilant Ingrevia Limited
Jubilant Ingrevia share price target & all analyst calls

byKotak SecuritiesHorizon: NA (inferred 1 year)3 Nov 2026via Zee Business (Live)

Entry₹562.8Inferred
Target₹970
Total upside +72.35%
Stop lossNot given
CMP₹572.41d ago
Active+1.71%+69.46%upside left 12 mo left
Follow Kotak Securities for new calls(92% target hit, 24 closed calls)Get alertsWatch JUBLINGREA for new buy/sell callsGet alertsSee 8 other Long-term calls on JUBLINGREASee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:24 pm IST
15 supporting4 neutral1 opposing
Supports the BUY call (15)

Jubilant Ingrevia (NSE:JUBLINGREA) Q2 FY27: Revenue ₹1,394 Crore, PAT ₹111 Crore

NewsGoogle News·2 Nov · 4d ago

(opens in new tab)

Jubilant Ingrevia posts record Q2 revenue, EBITDA up 51%

NewsGoogle News·2 Nov · 5d ago

(opens in new tab)

Jubilant Ingrevia Q2 FY27 Results & Acquisition Update

NewsGoogle News·2 Nov · 5d ago

(opens in new tab)

3 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·28 Oct · 1w ago

Jubilant Ingrevia Q2 results: Stock gains as much as 8% after Nutrition & Health Solutions aid earnings growth

NewsCnbc-Tv18·27 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (4)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·6 Nov · yesterday

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Jubilant Ingrevia

All analyst calls on Jubilant Ingrevia

More from Kotak Securities

Every call and its outcome